Visits | Enrolment/randomisation | D0 | D15 | M1 | M2 | M3 | M4 | M5 | M6 | M7 | M8 | M9 | End of participation |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Identification | X | ||||||||||||
Verification of selection criteria | X | ||||||||||||
Consent signature | X | ||||||||||||
Initial assessment – history | X | ||||||||||||
CT scan | X | X | X | X | X | X | |||||||
CT perfusion | X | X | X | X | |||||||||
Laboratory tests | X | X | X | X | X | X | X | X | X | X | X | X | X |
Classification | X | X | X | X | X | X | X | X | X | X | X | ||
Clinical examination | X | X | X | X | X | X | X | X | X | X | |||
Quality of life questionnaires | X | X | X | X | X | X | |||||||
Preparatory angiography | X | ||||||||||||
Scintigraphy | X | ||||||||||||
RE | X | ||||||||||||
Start of sorafenib treatment | X | ||||||||||||
Retreatment* | X | X | X | X | X | X | X | X | X | ||||
Cancer progression monitoring | X | X | X | X | X | X | X | X | X | X | |||
Sorafenib monitoring | X | X | X | X | X | X | X | X | X | X | |||
Concomitant medication | X | X | X | X | X | X | X | X | X | X | |||
Adverse events | X | X | X | X | X | X | X | X | X | X |